394 related articles for article (PubMed ID: 34011924)
21.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
22. RNA N
Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
[TBL] [Abstract][Full Text] [Related]
23. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
24. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
[TBL] [Abstract][Full Text] [Related]
25.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
26. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
27. Ferroptosis model system by the re-expression of BACH1.
Irikura R; Nishizawa H; Nakajima K; Yamanaka M; Chen G; Tanaka K; Onodera M; Matsumoto M; Igarashi K
J Biochem; 2023 Jul; 174(3):239-252. PubMed ID: 37094356
[TBL] [Abstract][Full Text] [Related]
28. MYCN and HIF-1 directly regulate
Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
[TBL] [Abstract][Full Text] [Related]
29. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
30. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
31. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
Lu F; Mu B; Jin G; Zhu L; Mu P
Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
[TBL] [Abstract][Full Text] [Related]
32. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
[TBL] [Abstract][Full Text] [Related]
33. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
34. CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of MYCN-amplificated neuroblastoma.
Zhou Y; Yan H; Zhou Q; Wang P; Yang F; Yuan Z; Du Q; Zhai B
Clin Transl Med; 2023 Jul; 13(7):e1328. PubMed ID: 37461251
[TBL] [Abstract][Full Text] [Related]
35. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
36. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
37.
De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
[TBL] [Abstract][Full Text] [Related]
38. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
39. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
40. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L; Mohammad MA; Milazzo G; Moreno-Smith M; Patel TD; Zorman B; Badachhape A; Hernandez BE; Wolf AB; Zeng Z; Foster JH; Aloisi S; Sumazin P; Zu Y; Hicks J; Ghaghada KB; Putluri N; Perini G; Coarfa C; Barbieri E
Nat Commun; 2022 Jun; 13(1):3728. PubMed ID: 35764645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]